Please assess the completion status of the following clinical trial:

Trial Title: Study of AVE1642 (IGF-1R/CD221) in Combination With Fulvestrant (Faslodex®) in Postmenopausal Patients With Advanced Hormono-dependent Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Post-menopausal women~* Aromatase inhibitor as the last hormonal treatment~* Breast adenocarcinoma with positive hormone receptor~* Measurable disease as per RECIST definition~Exclusion Criteria:~* ECOG performance status (PS) \> 2~* Prior exposure to fulvestrant or to an anti IGF-1R compound~* No evidence of hormonosensitivity~* HER 2-neu positive tumor~* More than one prior regimen of chemotherapy for metastatic disease~The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm A (Type: EXPERIMENTAL): None
- Arm B (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).